Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ALK – Abello issues interim financial report

ALK – Abello issues interim financial report

19th August 2009

ALK – Abello has issued its half-year financial report for the six-month period ended June 30th 2009.

The company said that its sales growth continued in the second quarter of the year, while organic growth in vaccine sales for the first half stood at ten per cent.

Revenue in the six-month period stood at 927 million Danish krone (106.5 million pounds), compared to 871 million Danish krone in the corresponding period in 2008.

Meanwhile, operating profit before depreciation and amortisation was 110 million Danish krone, a rise of 24 million Danish krone in comparison to the same period last year.

The company said that its outlook for 2009 remained unchanged from previous forecasts, with organic growth in allergy vaccine sales still predicted to stand at ten per cent or more.

In recent weeks, ALK – Abello announced that its dust mite allergy immunotherapy tablet has a “significant clinical effect” in people with asthma.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.